Ranbaxy 1st-qtr 2013 earnings plunge 90% as sales fall 34%

8 May 2013

India’s largest pharma company Ranbaxy Laboratories (BSE: 500359), which is majority owned by Japan’s Daiichi Sankyo, has posted first quarter 2013 financial results, showing the net income plunged 90% to 1.26 billion rupees ($23.4 million), while sales fell 34.2% to 24.40 billion rupees compared with the 2012 first quarter, when the company benefited from sales exclusivity in the USA for a generic version for a generic version of Pfizer’s all-time blockbuster Lipitor (atorvastatin).

Commenting on the business results for the quarter, Arun Sawhney, chief executive and managing director of Ranbaxy, said: "India and key emerging markets of East Europe + CIS and Africa + Middle East returned strong growth. The focus on differentiated products gained momentum during the quarter as we improved our market share in Absorica [isotretinoin] and received the rights to market desvenlafaxine in USA. We also continued to work towards optimizing overhead and other expenses."

Key highlights and developments:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK